Treatment of Non-alcoholic Fatty Liver Disease with Spleen Deficiency and Binding of Phlegm and Stasis Syndrome by <italic style="font-style: italic">Lanzhang Granules</italic> （蓝杖颗粒）： A Randomized Controlled Study

SHEN Nan; ZHENG Peiyong; FANG Yucheng; MIAO Hongyu; PAN Jielu; WANG Ruiqing; ZHANG Haiyan; XING Lianjun; YU Xiao

doi:10.13288/j.11-2166/r.2023.14.008

您当前的位置：

首页 >

文章列表页 >

Treatment of Non-alcoholic Fatty Liver Disease with Spleen Deficiency and Binding of Phlegm and Stasis Syndrome by Lanzhang Granules （蓝杖颗粒）： A Randomized Controlled Study

更新时间：2023-08-01

- Treatment of Non-alcoholic Fatty Liver Disease with Spleen Deficiency and Binding of Phlegm and Stasis Syndrome by Lanzhang Granules （蓝杖颗粒）： A Randomized Controlled Study
- Journal of Traditional Chinese Medicine Vol. 64, Issue 14, Pages: 1448-1454(2023)
- 作者机构：
  
  上海中医药大学附属龙华医院，上海市徐汇区宛平南路725号，200032
- 作者简介：
- 基金信息：
- DOI：10.13288/j.11-2166/r.2023.14.008
  CLC：
- Received：02 April 2023，
  
  Revised：2023-05-03，
  
  Published：17 July 2023
- 稿件说明：
移动端阅览
沈楠,郑培永,房雨晨等.蓝杖颗粒治疗非酒精性脂肪性肝病脾虚痰瘀互结证患者的随机对照研究[J].中医杂志,2023,64(14):1448-1454.

SHEN Nan,ZHENG Peiyong,FANG Yucheng,et al.Treatment of Non-alcoholic Fatty Liver Disease with Spleen Deficiency and Binding of Phlegm and Stasis Syndrome by Lanzhang Granules （蓝杖颗粒）： A Randomized Controlled Study[J].Journal of Traditional Chinese Medicine,2023,64(14):1448-1454.
沈楠,郑培永,房雨晨等.蓝杖颗粒治疗非酒精性脂肪性肝病脾虚痰瘀互结证患者的随机对照研究[J].中医杂志,2023,64(14):1448-1454. DOI： 10.13288/j.11-2166/r.2023.14.008.

SHEN Nan,ZHENG Peiyong,FANG Yucheng,et al.Treatment of Non-alcoholic Fatty Liver Disease with Spleen Deficiency and Binding of Phlegm and Stasis Syndrome by Lanzhang Granules （蓝杖颗粒）： A Randomized Controlled Study[J].Journal of Traditional Chinese Medicine,2023,64(14):1448-1454. DOI： 10.13288/j.11-2166/r.2023.14.008.

摘要

目的

评价蓝杖颗粒治疗非酒精性脂肪性肝病（NAFLD）脾虚痰瘀互结证的临床疗效及安全性。

方法

采用随机对照研究方法，将110例NAFLD脾虚痰瘀互结证患者分为治疗组和对照组各55例，两组患者在饮食及运动干预的基础上，治疗组口服蓝杖颗粒，对照组口服安慰剂，均每日1剂，疗程12周。治疗前后比较两组患者肝脏受控衰减参数（CAP）值、中医证候积分、血脂水平［包括总胆固醇（TC）、甘油三酯（TG）、高密度脂蛋白胆固醇（HDL-C）、低密度脂蛋白胆固醇（LDL-C）］、血糖相关指标［空腹血糖（FBG）、空腹胰岛素（FINS）］；比较两组治疗前及治疗4周、8周、12周时肝功能［丙氨酸氨基转移酶（ALT）、门冬氨酸氨基转移酶（AST）、谷氨酰转移酶（GGT）］，治疗后评价脂肪肝分级疗效、中医证候疗效和安全性。

结果

治疗组脂肪肝分级疗效总有效率为54.55%，高于对照组的14.55%（

＜0.01）。治疗组中医证候疗效总有效率为32.72%，高于对照组的14.55%（

＜0.01）。与本组治疗前比较，治疗组治疗后CAP值、中医证候积分、TC均降低，HDL-C升高（

＜0.05或

＜0.01）；治疗组治疗4、8周时AST降低（

＜0.05）。两组治疗后组间比较，治疗组CAP值明显低于对照组（

＜0.05）。两组患者治疗前后血糖相关指标差异均无统计学意义（

＞0.05）。治疗组不良反应发生1例，对照组为2例，两组均无严重不良事件出现。

结论

蓝杖颗粒治疗NAFLD脾虚痰瘀互结证，可有效降低患者肝脏脂肪浸润程度及血脂水平，改善临床症状，且安全性较好。

Abstract

Objective

To evaluate the clinical efficacy and safety of Lanzhang Granules （蓝杖颗粒， LZG） in the treatment of non-alcoholic fatty liver disease（NAFLD） with spleen deficiency and binding of phlegm and stasis syndrome（SDPSS）.

Methods

A randomized controlled study was conducted， in which 110 NAFLD patients with SDPSS were assigned to the treatment group （55 cases） and the control group （55 cases）. Behavioral intervention of diet and exercise was used as the basic treatment. Treatment group was given LZG， while the control group was given placebo orally， 1 dose a day for 12 weeks. The controlled attenuation parameters （CAP）， traditional Chinese medicine （TCM） syndrome score， blood lipid levels including total cholesterol （TC）， triglyceride （TG）， high-density lipoprotein cholesterol （HDL-C）， and low-density lipoprotein cholesterol （LDL-C）， and blood glucose-related indicators including fasting blood glucose （FBG） and fasting insulin （FINS） were compared between the two groups before and after treatment. Liver function indicators including alanine aminotransferase （ALT）， aspartate aminotransferase （AST） and glutamyl transferase （GGT） were compared between the two groups before treatment and at 4， 8， 12 weeks after treatment. The graded clinical efficacy of fatty liver， TCM syndrome clinical efficacy and safety were eva-luated after treatment.

Results

The total graded clinical efficacy of fatty liver in the treatment group （54.55%） was higher than that in the control group （14.55%，

＜0.01）. The total TCM syndrome efficacy in the treatment group （32.72%） was higher than that in the control group （14.55%，

＜0.01）. The CAP value， TCM syndrome score and TC decreased while HDL-C increased in the treatment group after treatment （

＜0.05 or

＜0.01）. The AST level in the treatment group decreased at 4 weeks and 8 weeks after treatment （

＜0.05）. The CAP value in the treatment group was significantly lower than that in the control group （

＜0.05）. There was no significant difference in blood glucose-related indicators between the two groups before and after treatment （

＞0.05）. Adverse reactions occurred in one case of the treatment group and 2 cases in the control group. There were no serious adverse reactions in both groups.

Conclusion

LZG in the treatment of NAFLD with SDPSS can effectively reduce the degree of liver fat infiltration and blood lipid levels， significantly relieve the clinical symptoms， and is of good safety.

关键词

Keywords

references

POWELL EE ， WONG VW ， RINELLA M . Non-alcoholic fatty liver disease ［J］. Lancet ， 2021 ， 397 （ 10290 ）： 2212 - 2224 .

ZHOU J ， ZHOU F ， WANG W ， et al . Epidemiological features of NAFLD from 1999 to 2018 in China ［J］. Hepatology ， 2020 ， 71 （ 5 ）： 1851 - 1864 .

LOOMBA R ， FRIEDMAN SL ， SHULMAN GI . Mechanisms and disease consequences of nonalcoholic fatty liver disease ［J］. Cell ， 2021 ， 184 （ 10 ）： 2537 - 2564 .

ARAÚJO AR ， ROSSO N ， BEDOGNI G . Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis： what we need in the future ［J］. Liver Int ， 2018 ， 38 （ S1 ）： 47 - 51 .

HUANG P ， YANG L ， LIU Y ， et al . Lanzhang granules ameliorate nonalcoholic fatty liver disease by regulating the PPARalpha signaling pathway ［J］. Evid Based Complement Alternat Med ， 2022 ， 2022 ： 1124901 . doi： 10. 1155/2022/1124901 http://dx.doi.org/10.1155/2022/1124901 .

中华医学会肝病学分会脂肪肝和酒精性肝病学组，中国医师协会脂肪性肝病专家委员会 . 非酒精性脂肪性肝病防治指南（2018年更新版）［J］. 实用肝脏病杂志， 2018 ， 21 （ 2 ）： 30 - 39 .

李军祥，陈治水，危北海 . 非酒精性脂肪性肝病中西医结合诊疗共识意见（2017年）［J］. 中国中西医结合杂志， 2011 ， 31 （ 2 ）： 155 - 158 .

中华中医药学会脾胃病分会 . 非酒精性脂肪性肝病中医诊疗专家共识意见［J］. 临床肝胆病杂志， 2017 ， 33 （ 12 ）： 2270 - 2274 .

LANCASTER GA ， DODD S ， WILLIAMSON P . Design and analysis of pilot studies： recommendations for good practice ［J］. J Eval Clin Pract ， 2004 ， 10 （ 2 ）： 307 - 312 .

中华人民共和国卫生部疾病控制司 . 中国成人超重和肥胖症预防控制指南［M］. 北京：人民卫生出版社， 2006 ： 2 - 3 .

瞬时弹性成像技术（TE）临床应用共识专家委员会 . 瞬时弹性成像技术（TE）临床应用专家共识（2015年）［J］. 中国肝脏病杂志（电子版）， 2015 ， 7 （ 2 ）： 12 - 18 .

YOUNOSSI Z ， ANSTEE QM ， MARIETTI M ， et al . Global burden of NAFLD and NASH： trends， predictions， risk factors and prevention ［J］. Nat Rev Gastroenterol Hepatol ， 2018 ， 15 （ 1 ）： 11 - 20 .

范建高，朱军，李新建，等 . 上海市成人脂肪肝患病率及其危险因素流行病学调查［J］. 中华肝脏病杂志， 2005 ， 13 （ 2 ）： 83 - 88 .

FOERSTER F ， GAIRING SJ ， MÜLLER L ， et al . NAFLD-driven HCC： safety and efficacy of current and emerging treatment options ［J］. J Hepatol ， 2022 ， 76 （ 2 ）： 446 - 457 .

DAVID K ， KOWDLEY KV ， UNALP A ， et al . Quality of life in adults with nonalcoholic fatty liver disease： baseline data from the nonalcoholic steatohepatitis clinical research network ［J］. Hepatology ， 2009 ， 49 （ 6 ）： 1904 - 1912 .

朱丹，孙婷婷，陈兰羽，等 . 脂肪性肝病中医药认识［J］. 辽宁中医药大学学报， 2020 ， 22 （ 5 ）： 70 - 73 .

王见义 . 王灵台从痰论治脂肪肝经验撷萃［J］. 辽宁中医杂志， 2011 ， 38 （ 5 ）： 832 - 833 .

SASSO M ， BEAUGRAND M ， LEDINGHEN VD ， et al . Controlled attenuation parameter （CAP）： a novel VCTE™ guided ultrasonic attenuation measurement for the evaluation of hepatic steatosis： preliminary study and validation in a cohort of patients with chronic liver disease from various causes ［J］. Ultrasound Med Biol ， 2010 ， 36 （ 11 ）： 1825 - 1835 .

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Discussion on the Scientific Connotation of Fortifying Spleen， Resolving Phlegm and Dispelling Stasis in the Treatment of Coronary Heart Disease under the Guidance of Dysfunctional High-Density Lipoprotein

Pathogenic Mechanisms of Spleen Deficiency-Phlegm Dampness in Obesity and Traditional Chinese Medicine Prevention and Treatment Strategies：from the Perspective of Immune Inflammation

Effects of Spleen Deficiency on Lipid Metabolism in Hyperlipidemia Model Rats Based on Gut Microbiota Sequencing and Fecal Metabolomics

Discussion on Occurrence and Development of Non-alcoholic Fatty Liver Disease based on Traditional Chinese Medicine Chronomedicine

Experience in Treating Diarrhea-predominant Irritable Bowel Syndrome Based on the Theory of Spleen Deficiency Generating Turbidity

Related Author

JIA Lianqun

WANG Qige

SUI Guoyuan

SONG Nan

CAO Huimin

KONG Liang

LV Meijun

CAO Yuan

Related Institution

Liaoning University of Traditional Chinese Medicine

Guangdong Provincial Academy of Chinese Medical Sciences

The Second Affiliated Hospital of Guangzhou University of Chinese Medicine/The Second Clinical Medical College of Guangzhou University of Chinese Medicine

School of Laboratory Animal Medicine，Liaoning University of Traditional Chinese Medicine

School of Integrated Traditional Chinese and Western Medicine，Liaoning University of Traditional Chinese Medicine

Address：No.16, Nanxiao street, Dongzhimen, Dongcheng District, Beijing Postal code：100700
Tel：010-64035632 Email：jtcmcn@188.com
Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19 京公网安备11010102007558号
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Treatment of Non-alcoholic Fatty Liver Disease with Spleen Deficiency and Binding of Phlegm and Stasis Syndrome by Lanzhang Granules （蓝杖颗粒）： A Randomized Controlled Study

DOI：10.13288/j.11-2166/r.2023.14.008

摘要

Abstract

关键词

Keywords

references